Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical
By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition
Alpha-1 antitrypsin deficiency (AATD), a rare genetic condition, can cause lung disease in adults with symptoms similar to chronic obstructive
By Christopher Rudolf, Volv Global An AI methodology for finding patients with rare diseases: Volv Global’s inTrigue The Case
By Volv Global SA and WODC EU contributors Executive Summary For decades, the pharmaceutical industry has faced the same
